Jefferies analyst Hisae Kawamoto upgraded Rohto Pharmaceutical (RPHCF) to Buy from Hold with a price target of 2,980 yen, up from 2,200 yen. While Japan sales growth is in the mid-single digits, the underlying resilience of Asia’s performance is “likely to be appreciated,” the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPHCF:
- Rohto Pharmaceutical initiated with a Neutral at UBS
- Rohto Pharmaceutical Reports Strong Growth in Latest Earnings
- Rohto Pharmaceutical Acquires OBAGI Trademarks in Japan
- Rohto Pharmaceutical Revises Earnings and Dividend Forecasts Upward
- Rohto Pharmaceutical Reports Strong Financial Growth and Strategic Expansion